Table I.

Multivariate analysis of progression-free survival (PFS) and overall survival (OS).

	PFS HR (95% CI)	P value	OS HR (95% CI)	P value
Age <65 years	0.988 (0.722–1.352)	0.9397	0.790 (0.549–1.137)	0.2041
No extranodal disease	0.804 (0.604–1.070)	0.1340	0.872 (0.633–1.201)	0.4013
ECOG performance status 0–1	0.584 (0.359–0.949)	0.0299*	0.454 (0.263–0.782)	0.0045*
MIPI
High risk	2.266 (1.431–3.589)	0.0005*	2.372 (1.401–4.016)	0.0013*
Intermediate risk	1.624 (1.081–2.440)	0.0195*	1.678 (1.046–2.692)	0.0319*
One prior line of therapy	0.651 (0.448–0.946)	0.0245*	0.695 (0.459–1.055)	0.0873
Non-bulky disease (<5 cm)	0.703 (0.528–0.938)	0.0164*	0.608 (0.438–0.844)	0.0029*
Non-blastoid histology	0.442 (0.303–0.646)	<0.0001*	0.397 (0.259–0.608)	<0.0001*
No bone marrow involvement	0.936 (0.709–1.236)	0.6411	0.733 (0.537–1.002)	0.0511
Study PCYC-1104 (phase II)	0.848 (0.589–1.223)	0.3779	0.757 (0.499–1.150)	0.1923
Study MCL2001 (phase II)	1.294 (0.914–1.831)	0.1465	0.924 (0.628–1.358)	0.6861

CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; MIPI, mantle cell lymphoma international prognostic index.

^*Significant.